Evidence map›Paper›PMID 33270684›Full record

ArticlePloS one2020

Explaining the increment in coronary heart disease mortality in Mexico between 2000 and 2012.

Carmen Arroyo-Quiroz, Martin O'Flaherty, Maria Guzman-Castillo, Simon Capewell, Eduardo Chuquiure-Valenzuela, Carlos Jerjes-Sanchez, Tonatiuh Barrientos-Gutierrez

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Carmen Arroyo-QuirozCenter for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico.ORCID 0000-0002-4934-0394
Martin O'FlahertyInstitute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom.
Maria Guzman-CastilloPopulation Research Unit, Faculty of Social Sciences, University of Helsinki, Helsinki, Finland.
Simon CapewellInstitute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom.
Eduardo Chuquiure-ValenzuelaNational Institute of Cardiology, Mexico City, Mexico.
Carlos Jerjes-SanchezEscuela de Medicina y Ciencias de la Salud, Instituto Tecnológico de Monterrey, Instituto de Cardiología y Medicina Vascular, TecSalud, Monterrey, Mexico.
Tonatiuh Barrientos-GutierrezCenter for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico.
University of Liverpool · GBInstituto Nacional de Cardiología · MXInstituto Nacional de Salud Pública · MXTecnológico de Monterrey · MXUniversidad Autónoma Metropolitana · MXUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMexico is still in the growing phase of the epidemic of coronary heart disease (CHD), with mortality increasing by 48% since 1980. However, no studies have analyzed the drivers of these trends. We aimed to model CHD deaths between 2000 and 2012 in Mexico and to quantify the proportion of the mortality change attributable to advances in medical treatments and to changes in population-wide cardiovascular risk factors.

methodsWe performed a retrospective analysis using the previously validated IMPACT model to explain observed changes in CHD mortality in Mexican adults. The model integrates nationwide data at two-time points (2000 and 2012) to quantify the effects on CHD mortality attributable to changes in risk factors and therapeutic trends.

resultsFrom 2000 to 2012, CHD mortality rates increased by 33.8% in men and by 22.8% in women. The IMPACT model explained 71% of the CHD mortality increase. Most of the mortality increases could be attributed to increases in population risk factors, such as diabetes (43%), physical inactivity (28%) and total cholesterol (24%). Improvements in medical and surgical treatments together prevented or postponed 40.3% of deaths; 10% was attributable to improvements in secondary prevention treatments following MI, while 5.3% to community heart failure treatments.

conclusionsCHD mortality in Mexico is increasing due to adverse trends in major risk factors and suboptimal use of CHD treatments. Population-level interventions to reduce CHD risk factors are urgently needed, along with increased access and equitable distribution of therapies.

Indexed as

AdultAgedAged, 80 and overCoronary DiseaseFemaleHumansMaleMexicoMiddle AgedMortalityRetrospective StudiesRisk FactorsUncertainty

Identifiers

PMID33270684
PMCPMC7714134
OpenAlexW3107928787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.